Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-B7-H3-UCAR-T
- Development stage
- Unknown
- Lead developer
- Shanghai ChangZheng Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-B7-H3-UCAR-T is an allogeneic, "universal" chimeric antigen receptor (CAR) T-cell therapy targeting B7-H3 (CD276), a checkpoint molecule overexpressed in various solid tumors, including sarcomas. Developed by Shanghai Changzheng Hospital, this therapy utilizes T-cells from healthy donors that are genetically modified to express a CAR specific for B7-H3 and further engineered to reduce the risk of graft-versus-host disease (GvHD) and host-versus-graft rejection, allowing for "off-the-shelf" administration. It is currently being evaluated in clinical trials for patients with relapsed or refractory bone and soft tissue sarcomas after failure of standard therapies.
- Other names
- Anti-B7-H3 universal CAR-TAnti-B-7-H3 universal CAR-TAnti-B 7-H3 universal CAR-TB7-H3-targeted universal CAR-T cellsB-7-H3-targeted universal CAR-T cellsB 7-H3-targeted universal CAR-T cells
02
Targets
B7-H3
Beyond the preview
Go deeper on Anti-B7-H3-UCAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-B7-H3-UCAR-T.